本文選題：支氣管哮喘　切入點(diǎn)：MMP-9　出處：《青海大學(xué)》2013年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：本研究通過采用酶聯(lián)免疫吸附（Enzyme-Linked ImmunosorbnentAssay，ELISA）實(shí)驗(yàn)方法測(cè)定治療前后血清中MMP-9、TIMP-1水平的變化，觀察白三烯受體拮抗劑（孟魯司特鈉）對(duì)輕度持續(xù)性支氣管哮喘患者血清中MMP-9、TIMP-1水平的影響。 方法：選取輕度持續(xù)性支氣管哮喘患者61例，隨機(jī)分成治療組29例和對(duì)照組32例，，治療組使用常規(guī)治療+孟魯司特鈉10mg每日一次口服,療程為7-14天，對(duì)照組使用常規(guī)治療,療程為7-14天，采用ELISA法測(cè)定兩組治療前后血清MMP-9、TIMP-1水平，并對(duì)其變化進(jìn)行分析比較。 結(jié)果：①治療7-14天后，治療組血清MMP-9明顯低于對(duì)照組(p0.05)，分別為22.75±6.51ng/ml、28.93±7.59ng/ml；治療組治療前患者血清MMP-9水平為29.07±7.83ng/ml，明顯高于治療組治療后(p0.05)。②治療7-14天后，治療組血清TIMP-1明顯低于對(duì)照組(p0.05)，分別為10.74±4.14ng/ml、13.75±2.59ng/ml；治療組治療前患者血清TIMP-1水平為13.76±3.53ng/ml，明顯高于治療組治療后(P0.05)。 結(jié)論：孟魯司特鈉可明顯降低輕度持續(xù)性支氣管哮喘患者血清中MMP-9和TIMP-1的水平。MMP-9和TIMP-1的水平可作為輕度持續(xù)性支氣管哮喘患者療效判斷的指標(biāo)。孟魯司特鈉可能會(huì)通過下調(diào)支氣管哮喘患者血清MMP-9和TIMP-1的水平，減少氣道細(xì)胞外基質(zhì)沉積。
[Abstract]:Objective: to determine the level of MMP-9 and TIMP-1 in serum before and after treatment by Enzyme-Linked Immunosorbent Assayia Elisa. To observe the effect of leukotriene receptor antagonist (montelukast sodium) on the level of MMP-9 and TIMP-1 in patients with mild persistent bronchial asthma. Methods: Sixty-one patients with mild persistent bronchial asthma were randomly divided into treatment group (n = 29) and control group (n = 32). The treatment group was treated with 10 mg montelukast sodium once a day for 7-14 days, and the control group was treated with routine therapy. The serum levels of MMP-9 and TIMP-1 were measured by ELISA before and after treatment for 7-14 days. Results after 7 to 14 days of treatment, the serum MMP-9 of the treatment group was significantly lower than that of the control group (22.75 鹵6.51 ng / ml, 28.93 鹵7.59 ng / ml, respectively), and the serum MMP-9 level of the treatment group was 29.07 鹵7.83 ng / ml, which was significantly higher than that of the control group (P 0.05.2, 7-14 days after treatment). The serum TIMP-1 in the treatment group was significantly lower than that in the control group (10.74 鹵4.14 ng / ml, 13.75 鹵2.59 ng / ml, respectively), and the serum TIMP-1 level in the treatment group was 13.76 鹵3.53 ng / ml, which was significantly higher than that in the treatment group after treatment (P 0.05). Conclusion: montelukast sodium can significantly reduce the levels of MMP-9 and TIMP-1 in patients with mild persistent bronchial asthma. MMP-9 and TIMP-1 levels can be used as an index to judge the curative effect of patients with mild persistent bronchial asthma. By down-regulating the levels of serum MMP-9 and TIMP-1 in patients with bronchial asthma, Reduce airway extracellular matrix deposition.
【學(xué)位授予單位】：青海大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類號(hào)】：R562.25;R96

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 武玉清;白三烯受體拮抗劑孟魯司特的研究進(jìn)展[J];國(guó)外醫(yī)學(xué).藥學(xué)分冊(cè);2003年05期

2 金哲,秦培順,張志軍;TIMP-1與MMP-9,MMP-3的平衡與哮喘患兒病情之間關(guān)系的研究以及糖皮質(zhì)激素對(duì)其影響[J];吉林醫(yī)學(xué);2005年10期

3 季偉;周衛(wèi)芳;朱燦紅;;白三烯受體拮抗劑對(duì)哮喘模型肺組織TIMP-1的影響[J];臨床兒科雜志;2005年12期

4 喬紅梅;魯繼榮;成煥吉;劉麗;馬青山;傅文永;趙芳興;;白三烯受體拮抗劑對(duì)哮喘大鼠基質(zhì)金屬蛋白酶-9及其抑制劑表達(dá)的影響[J];臨床兒科雜志;2006年08期

5 胡江彥;何濱;;支氣管哮喘治療新進(jìn)展[J];臨床肺科雜志;2011年04期

6 韓照升,徐軍,李時(shí)悅,鐘南山;支氣管哮喘患者氣道粘膜活檢組織MMP-9表達(dá)的臨床研究[J];中國(guó)實(shí)用內(nèi)科雜志;2002年06期

7 王麗新,吳銀根;實(shí)驗(yàn)性哮喘大鼠氣道重塑的形態(tài)學(xué)變化[J];中西醫(yī)結(jié)合學(xué)報(bào);2003年01期

8 滕鴻,梁宗安,劉春濤;白三烯受體拮抗劑對(duì)哮喘小鼠氣道重構(gòu)及基質(zhì)金屬蛋白酶-2表達(dá)水平的干預(yù)作用[J];中國(guó)呼吸與危重監(jiān)護(hù)雜志;2004年05期

9 趙慶偉;;白三稀受體拮抗劑治療支氣管哮喘臨床觀察[J];中國(guó)實(shí)用醫(yī)藥;2011年04期

10 ;支氣管哮喘防治指南(支氣管哮喘的定義、診斷、治療和管理方案)[J];中華哮喘雜志(電子版);2008年01期

相關(guān)碩士學(xué)位論文 前2條

1 蘇艷;白三烯受體拮抗劑對(duì)哮喘大鼠氣道細(xì)胞外基質(zhì)重塑的影響[D];河北醫(yī)科大學(xué);2009年

2 賀向紅;慢性阻塞性肺疾病患者肺組織基質(zhì)金屬蛋白酶-9的分布與表達(dá)[D];天津醫(yī)科大學(xué);2012年

本文編號(hào)：1586680